Antimicrobial and antibiofilm activities of Cu(II) Schiff base complexes against methicillin-susceptible and resistant Staphylococcus aureus

Chung, Pooi Yin; Khoo, R.; Liew, Hui Shan; Low, May Lee

doi:10.1186/s12941-021-00473-4

Cited by 14 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antimicrobial activities of the Cu(II) complexes of Schiff bases can be improved with the combination of well-established antibiotics. In their study, Chung et al tested Cu(II) complexes of Schiff base ligands, SBD2 and SBD4 (Figure 7A,B, respectively) individually and in combination with the antibiotics oxacillin (a penicillin derivative [77]) and vancomycin (a glycopeptide antibiotic [78]) towards microbes and biofilm [79]. These types of antibiotics target the peptidoglycan bacteria wall synthesis [80].…”

Section: Cu(ii) Coordination Complexesmentioning

confidence: 99%

“…The fractional inhibition concentration (FIC), which is used to test the interactions between two or more drugs that are intended to be used in combination, was calculated [81]. Equation ( 1) can be used to calculate the FIC value, where MIC A and MIC B represent the minimal inhibitory concentration of compound A and B; C A and C B correspond to the concentration of the drugs [79]. As a standard measurement for FIC, values ranging from 0.0 ≤ 0.50 are considered a synergistic effect; from 0.50 ≤ 4.0, additive interaction and values above 4.00 are considered to have an antagonist effect.…”

Section: Cu(ii) Coordination Complexesmentioning

confidence: 99%

“…Chung et al observed that the Cu(II) compounds SBD2 and SBD4 exhibited bacteriostatic effects against MRSA, with an MIC of 8 µg/mL and 32 µg/mL, respectively [79]. The combinations of SBD2 (0.5 to 8 µg/mL) and oxacillin (1 to 16 µg/mL) exhibit additive or synergistic bacteriostatic effect.…”

Section: Cu(ii) Coordination Complexesmentioning

confidence: 99%

See 2 more Smart Citations

Copper-Based Antibiotic Strategies: Exploring Applications in the Hospital Setting and the Targeting of Cu Regulatory Pathways and Current Drug Design Trends

Orta-Rivera,

Meléndez-Contés,

Medina-Berríos

et al. 2023

Inorganics

View full text Add to dashboard Cite

Classical antibacterial drugs were designed to target specific bacterial properties distinct from host human cells to maximize potency and selectivity. These designs were quite effective as they could be easily derivatized to bear next-generation drugs. However, the rapid mutation of bacteria and their associated acquired drug resistance have led to the rise of highly pathogenic superbug bacterial strains for which treatment with first line drugs is no match. More than ever, there is a dire need for antibacterial drug design that goes beyond conventional standards. Taking inspiration by the body’s innate immune response to employ its own supply of labile copper ions in a toxic attack against pathogenic bacteria, which have a very low Cu tolerance, this review article examines the feasibility of Cu-centric strategies for antibacterial preventative and therapeutic applications. Promising results are shown for the use of Cu-containing materials in the hospital setting to minimize patient bacterial infections. Studies directed at disrupting bacterial Cu regulatory pathways elucidate new drug targets that can enable toxic increase of Cu levels and perturb bacterial dependence on iron. Likewise, Cu intracellular chelation/prochelation strategies effectively induce bacterial Cu toxicity. Cu-based small molecules and nanoparticles demonstrate the importance of the Cu ions in their mechanism and display potential synergism with classical drugs.

show abstract

Section: Cu(ii) Coordination Complexesmentioning

confidence: 99%

Section: Cu(ii) Coordination Complexesmentioning

confidence: 99%

See 1 more Smart Citation

Copper-Based Antibiotic Strategies: Exploring Applications in the Hospital Setting and the Targeting of Cu Regulatory Pathways and Current Drug Design Trends

Orta-Rivera,

Meléndez-Contés,

Medina-Berríos

et al. 2023

Inorganics

View full text Add to dashboard Cite

show abstract

“…In their study, Chung et al tested Schiff bases derivative complexes, SBD2 and SBD4 (Figures 7A and 7B, respectively) individually and in combination with antibiotics such as oxacillin (a penicillin derivative [78]) and vancomycin (a glycopeptidic antibiotic [79]) towards microbes and antibiofilm [80]. These types of antibiotics target the peptidoglycan bacteria wall synthesis [81].…”

Section: Cu(ii) Coordination Complexes a Ligand To Metal Synergistic ...mentioning

confidence: 99%

“…Equation (1) can be used to calculate the FIC value. Where MICA and MICB represent the minimal inhibitory concentration of compound A and B, CA and CB correspond to the concentration of the drugs [80]. As a standard measurement for FIC, values ranging from 0.0 ≤ 0.50 are considered a synergistic effect, from 0.50 ≤ 4.0 additive interaction and values above 4.00 are considered to have an antagonist effect.…”

Section: Cu(ii) Coordination Complexes a Ligand To Metal Synergistic ...mentioning

confidence: 99%

Copper Based Antibacterial Compounds: Potential Targeting Pathways and Current Drug Design Trends.

Orta-Rivera¹,

Meléndez-Contés²,

Rivera-Berríos³

et al. 2023

Preprint

View full text Add to dashboard Cite

Classical antibacterial drugs were designed to target specific bacterial properties distinct from host human cells to maximize potency and selectivity. These designs were quite effective as they could be easily derivatized to bear next generation drugs. However, the rapid mutation of bacteria and their associated acquired drug resistance have led to the rise of highly pathogenic superbug bac-terial strains for which treatment with first line drugs is no match. More than ever, there is a dire need for antibacterial drug design that goes beyond conventional standards. Taking inspiration by the body’s innate immune response to employ its own supply of labile copper ions in a toxic attack against pathogenic bacteria, which have a very low Cu tolerance, this review article examines the feasibility of Cu-centric strategies for antibacterial preventative and therapeutic applications. Promising results are shown for the use of Cu-containing materials in the hospital setting to minimize patient bacterial infections. Studies directed at disrupting bacterial Cu regulatory pathways elucidate new drug targets that can enable toxic increase of Cu levels and perturb bac-terial dependence on iron. Likewise, Cu intracellular chelation/prochelation strategies effectively induce bacterial Cu toxicity. Cu-based small molecules and nanoparticles demonstrate the im-portance of the Cu ions in their mechanism and display potential synergism with classical drugs.

show abstract

Highly Fluorescent π-Conjugated Azomethines and Divalent Metal Complexes as Antibacterial and Antibiofilm Nominees

Baydeniz,

Uçan,

Sevgi

et al. 2024

J Fluoresc

View full text Add to dashboard Cite

Abstractπ-Conjugated azomethine ligands differing in the naphthalene or phenylmethane-centered core structure and their divalent cobalt, nickel, copper, and zinc metal complexes were prepared and well-characterized by spectral analyses in solid state. Magnetic natures of the complexes were determined by magnetic susceptibility measurements in solid-state. Their remarkable photophysical characteristics were recorded by Uv–vis and Fluorescence spectroscopic techniques. At their excitation wavelenght of 265 nm, all molecules exhibited triple fluorescence emission bands with promising intensities above 673 nm in near infra-red region. Antibacterial and antibiofilm activities of the π-conjugated azomethines are promising for potential applications in medical and healthcare settings. Hence, the antibacterial/antibiofilm activity of the π-conjugated azomethine ligands and their metal complexes against some clinically important bacteria namely Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Proteus mirabilis was investigated, and the obtained results have shown that the ligands and complexes had a remarkable antibacterial effect, especially on Proteus mirabilis. Metal complexes have been found to have a significant inhibitory effect on biofilm formation by MRSA, MSSA, and P. mirabilis compared to ligands. The copper (II) complex of ligand-2 showed the highest inhibition percentage, significantly reducing biofilm formation for MRSA and MSSA. Furthermore, cobalt (II) complexes of the ligands selectively inhibited the growth of the opportunistic pathogen P. mirabilis biofilms, indicating that metal complexes might be a good choice for future antibiofilm studies.

show abstract

Antimicrobial and antibiofilm activities of Cu(II) Schiff base complexes against methicillin-susceptible and resistant Staphylococcus aureus

Cited by 14 publications

References 26 publications

Copper-Based Antibiotic Strategies: Exploring Applications in the Hospital Setting and the Targeting of Cu Regulatory Pathways and Current Drug Design Trends

Copper-Based Antibiotic Strategies: Exploring Applications in the Hospital Setting and the Targeting of Cu Regulatory Pathways and Current Drug Design Trends

Copper Based Antibacterial Compounds: Potential Targeting Pathways and Current Drug Design Trends.

Highly Fluorescent π-Conjugated Azomethines and Divalent Metal Complexes as Antibacterial and Antibiofilm Nominees

Contact Info

Product

Resources

About